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IT-901 is a novel and selective NF-κB inhibitor with promising activityin pre-clinical models. Here we show that treatment of chronic lym-phocytic leukemia cells (CLL) with IT-901 effectively interrupts NF-κB
transcriptional activity. CLL cells exposed to the drug display elevated
mitochondrial reactive oxygen species, which damage mitochondria,
limit oxidative phosphorylation and ATP production, and activate intrin-
sic apoptosis. Inhibition of NF-κB signaling in stromal and myeloid cells,
both tumor-supportive elements, fails to induce apoptosis, but impairs
NF-κB-driven expression of molecules involved in cell-cell contacts and
immune responses, essential elements in creating a pro-leukemic niche.
The consequence is that accessory cells do not protect CLL cells from IT-
901-induced apoptosis. In this context, IT-901 shows synergistic activity
with ibrutinib, arguing in favor of combination strategies. IT-901 is also
effective in primary cells from patients with Richter syndrome (RS). Its
anti-tumor properties are confirmed in xenograft models of CLL and in RS
patient-derived xenografts, with documented NF-κB inhibition and signif-
icant reduction of tumor burden. Together, these results provide pre-clin-
ical proof of principle for IT-901 as a potential new drug in CLL and RS.  
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ABSTRACT
Introduction
Nuclear factor-kappa B (NF-κB) is a ubiquitous transcription factor, composed of
a family of five structurally related proteins, including p50 (NF-κB1), p52 (NF-κB2),
p65 (RelA), RelB and c-Rel, which can form homo- and hetero-dimers. While 
NF-κB is normally kept inactivated through binding to the inhibitory subunit (IκB),
IκB phosphorylation and degradation releases the dimer that translocates to the
nucleus and binds to target sequences on DNA.1-3 
NF-κB signaling plays essential roles in inflammation, immune responses, prolif-
eration, and cell survival.4-6 In cancer cells, NF-κB promotes tumor growth by con-
tributing to maintenance/expansion of tumor-initiating cells and by shaping the
tumor microenvironment.7 Deregulated NF-κB signaling is a common finding in
most, if not all, B-lymphoid malignancies.8 
Chronic lymphocytic leukemia cells (CLL) exhibit high constitutive NF-κB acti-
vation compared to normal B lymphocytes, with the p65 subunit being the most
active and relevant for transcription.9-12 Moreover, p65 levels correlate with
leukemic cell survival in vitro, as well as with tumor burden and shorter lymphocyte
doubling time.13,14 NF-κB is activated by B-cell receptor (BCR) signaling, the driving
force behind CLL pathogenesis and progression.15 However, additional signals from
the micro-environment increase NF-κB activity and enhance CLL cell survival, with
members of the Bcl-2 family among the most important transcriptional targets.16-19  
Approximately 5-10% of CLL patients undergo transformation of the leukemia
into an aggressive diffuse large B-cell lymphoma (DLBCL), a complication known
as Richter syndrome (RS).20 The clinical outcome of RS is generally poor, with a
median survival of a few months, mainly because of limited therapeutic options
and responses.21 In a significant proportion of cases, RS patients carry activating
mutations in genes belonging to the NF-κB pathway.22  
Given the central role of the NF-κB signals in CLL and in
RS transformation,  and specifically of the p65 subunit,
this complex represents an important therapeutic target,
even if so far none of the studied inhibitors have entered
clinical trials. IT-901 was recently reported as an NF-κB
inhibitor (acting through c-Rel and p65) and redox modu-
lator, showing significant activity in mouse models of
graft-versus-host disease (GvDH) and graft-versus-lym-
phoma (GvL), as well as in a xenograft model of human-
B-cell lymphoma, mediating promising anti-lymphoma
effects.23,24  
The aim of this work is to determine the in vitro and 
in vivo effects of IT-901 in CLL and RS primary cells and
derived line models.
Methods
Cell lines and primary samples
Leukemic cells were purified using Ficoll-Hypaque (Sigma-
Aldrich, Milan, Italy) from peripheral blood (PB) of CLL patients or
lymph node (LN) of RS patients presenting with typical morphol-
ogy and immunophenotype.21 Samples were obtained at Weill
Cornell Medicine after written informed consent in accordance
with institutional guidelines and the Declaration of Helsinki. The
referring physician provided molecular and genetic characteriza-
tion of patients' samples. Normal circulating B cells were purified
from healthy donors. Mec-1 and OSU-CLL CLL cell lines were
obtained from the Leibniz Institute DSMZ-German Collection of
Microorganisms and Cell Cultures and Ohio State University,
respectively, and cultured in RPMI+10% fetal bovine serum (FBS).
HS-5 stromal cells were obtained from ATCC and cultured in
DMEM+10% FCS. 
Metabolic assays
Chronic lymphocytic leukemia  cells were exposed to vehicle
(0.02% DMSO in RPMI-1640, indicated as NT) or IT-901 (10 mM
in the same solution as vehicle) for 6 hours (h), before dynamically
measuring the metabolic profile using the XF96e Extracellular Flux
Analyzer (Seahorse Bioscience, North Billerica, MA, USA). Cells
(5x105 for primary cells and 105 for cell lines) were seeded in spe-
cialized tissue culture plates, coated with CellTak (BD
Biosciences). An hour before measurement, cells were incubated
at 37°C in a CO2-free atmosphere. Oxygen consumption rate
(OCR), an indicator of mitochondrial respiration, was measured in
basal conditions and following addition of specific drugs,
oligomycin (1 mM), carbonilcyanide p-triflouromethoxyphenylhy-
drazone (FCCP, 1 mM) and Rotenone/Antimycin A (0.5 mM) able
to interfere with different steps of the oxidative phosphorylation
(OXPHOS) process (XF Cell Mito Stress test kit, Seahorse
Bioscience). Maximal OCR and ATP production were measured.
In all experiments, measurements were performed in quadrupli-
cates. 
In vivo experiments and treatments
Mec-1 (5x105) cells were intravenously injected (i.v; tail vein)
in 8-week old NOD/SCID/gamma chain–/– (NSG) mice and left
to engraft for ten days before starting treatment. Mice received
intra-peritoneal (i.p.) injection of IT-901 (15 mg/kg) or vehicle
(Polyethene glycol-12 Glycerol-Dimyristate, GDM 4% in PBS).
At the end of treatment, mice were euthanized, organs collected
and partially dismantled to obtain single cell suspension or for-
malin-fixed for immunohistochemistry analyses. Mec-1 cell dis-
tribution in the different organs was analyzed by flow cytome-
try, after staining single cell suspensions with anti-human-
CD19FITC and -CD45PerCP antibodies to identify leukemic
cells. A different set of mice was monitored for survival.
Richter syndrome model
Primary RS cells were obtained from PB or LN biopsies of clini-
cally diagnosed RS patients. Purified cells (20x106) or LN fragments
were injected sub-cutaneously (s.c., double flank) in 6-week old
NSG mice and left to engraft. Tumor masses were then collected,
partially dismantled and re-implanted in new animals for several
passages to obtain a stable model of RS. Genetic stability and rela-
tionship to the original tumor was confirmed by exome sequenc-
ing (T Vaisitti and JN Allan, 2017, manuscript in preparation).
After several passages in vivo, RS cells obtained from the tumor
mass were put in culture over a stromal layer of HS-5 cells and
were able to grow in vitro, maintaining the original genetic and
phenotypic characteristics. RS-PDX models were established
while TV and SD were Visiting Scientists at Weill Cornell
Medicine. The Institutional Animal Care and Use Committee
approved all the experiments involving mice.
Additional details are provided in the Online Supplementary
Appendix.
Results
IT-901 blocks NF-κB activity in primary CLL cells and
derived cell lines
IT-901 is a recently described NF-κB inhibitor, with
promising activity in mouse models of GvHD  and lym-
phoma.23,24 In consideration of the high levels of consti-
tutive NF-κB activation in CLL and in RS cells, the aim
of this work is to provide pre-clinical evidence of the
therapeutic effects of IT-901. In the experimental setting
adopted, maximal NF-κB activation was obtained by
culturing primary CLL cells for 6 h over a layer of HS-5,
a stromal cell line with documented nurturing properties
for CLL cells.25 By using an ELISA assay that measures
NF-κB interactions with its DNA consensus sequences,
we confirmed significant upregulation of p65 and p50
DNA-binding activities compared to the basal condition
(Figure 1A). Conversely, addition of IT-901 during the
co-culture period significantly decreased DNA binding
of both subunits, with p65 being most sensitive (Figure
1A). In line with previous reports, IT-901 limited the
DNA binding ability of c-Rel (Online Supplementary
Figure S1A); however, in CLL cells this subunit is
expressed and active at very low levels, suggesting that
the main effects of the drug are through p65. Inhibition
of NF-κB transcriptional activity was confirmed using
nuclear extracts of Mec-1 and OSU-CLL, two CLL cell
lines, where NF-κB activity is independent of micro-
environmental conditions (Figure 1B and Online
Supplementary Figure S1B). 
Diminished expression of p65 and p50 in nuclear and
cytosolic fractions following IT-901 exposure was docu-
mented in primary cells and cell lines, suggesting that the
drug induces degradation of the complex (Figure 1C, G
and D, H, respectively). The same treatment also
decreased the expression of the inhibitory subunit IκBα
both in the phosphorylated and non-phosphorylated
forms, in primary CLL cells (Figure 1E) and cell lines
(Figure 1F), in line with the hypothesis that IT-901 inter-
acts with the NF-κB-IκB cytoplasmic complex triggering
its degradation.
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IT-901 induces mitochondrial reactive oxygen species
accumulation
Consistent with the documented cross-talk between
NF-κB and ROS,26,27 a prominent and dose-dependent
increase in mitochondrial reactive oxygen species (mROS)
was measured starting 6 h after treatment with IT-901,
both in primary cells and in cell lines (Figure 2A and Online
Supplementary Figure S2A, respectively). 
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Figure 1. IT-901 blocks nuclear factor-kappa B (NF-κB) activity in primary chronic lymphocytic leukemia (CLL) cells and derived cell line. (A) DNA binding activity of
the p65 and p50 subunits in primary CLL cells (n=13) was analyzed using an ELISA kit, applying the same amount of nuclear extracts. Leukemic cells were co-cul-
tured on a stromal layer (HS-5) to maximize the activation of the pathway, in the presence of increasing doses of drug or vehicle (NT) for 6 hours (h). (B) Cumulative
DNA binding activity of NF-κB (p65 and p50) in 2 different cell line models of CLL, Mec-1 (n=5), and OSU-CLL (n=3). (C, D, G and H) Cytoplasmic (C) and nuclear (N)
fractions obtained from primary CLL cells (C) or cell lines (D) cultured as indicated above were resolved by SDS-PAGE and blotted with specific antibodies to detect
the expression of NF-κB1 subunits p105/p50 (arrow head) and RelA (p65). Lamin A/C and β-tubulin were used as nuclear and cytoplasmic markers, respectively.
Nuclear p65 and p50 band intensities in primary CLL samples and CLL cell lines are reported in (G) and (H), respectively. (E and F) Total lysates from primary CLL
cells (E) or CLL cell lines (F) cultured alone and exposed to different doses of IT-901 or vehicle (NT) for 6 h were resolved by SDS-PAGE and expression of the NF-κB
complex analyzed using specific antibodies. Actin was used as a loading control. OD: optical density.
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In principle, progressive mROS accumulation could be
caused by increased production or impaired scavenging,
due, at least in part, to the interruption of NF-κB-depen-
dent transcription of genes coding for scavenging
enzymes.26,27 The finding of a significantly decreased
expression of the NF-κB-regulated catalase enzyme
favored the hypothesis of a contribution of impaired scav-
enging to increased mROS (Figure 2B and Online
Supplementary Figure S2B).
Elevated mROS levels decreased mitochondrial mem-
brane potential (Dfm), as shown by using the potentio-
metric probe JC-1, whose decrease in red fluorescence
depends solely on mitochondrial depolarization (Figure
2C). Similar results were obtained in CLL cell lines, with a
dose-dependent loss of (Dfm),  starting at the 2.5 mM dose
(Online Supplementary Figure S2C). These results were con-
firmed using the cationic dye TMRM that binds to the
inner membrane of intact mitochondria (Online
Supplementary Figure S2D).
Mitochondrial respiration is severely compromised 
following IT-901 treatment
Consistent with the finding of high levels of mROS in
IT-901-treated CLL cells, mitochondrial energetic
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Figure 2. IT-901 induces mitochondrial damage and compromises mitochondrial respiration. (A) Representative plots and cumulative data of mitochondrial reactive
oxygen species (mROS) concentration in chronic lymphocytic leukemia (CLL) cells. Data are represented as fold change (FC) over the vehicle (n=10). (B) Box plot
reporting the catalase (CAT) mRNA expression levels in vehicle (NT)- or IT-901-treated primary cells (n=10). (C) Representative plots and cumulative data of inner
mitochondrial membrane potential (DΦm) in primary CLL cells (n=10) exposed to vehicle (NT) or increasing doses of IT-901 for 6 hours (h).  CCCP was used as positive
control. (D) Dynamic mitochondrial metabolic profile (OCR; pmoles/min) of a representative CLL patient treated with vehicle (red line) or IT-901 10 mM (blue line) for
6 h. Maximal respiration (calculated as: OCR after FCCP injection-late OCR measurement after RT/AA addition) and ATP production (calculated as last rate measure-
ment of OCR before Oligo injection-minimum rate measurement after Oligo injection) in primary CLL patients (n=7). (E) Box plots reporting ATP-synthase (ATP5A1)
and Cytochrome C Oxidase Assembly Protein (SCO2) mRNA expression levels in vehicle- or IT-901-treated primary cells (n=7). CCCP: carbonyl cyanide m-chlorophenyl
hydrazone; Oligo: oligomycin; FCCP: carbonyl cyanide p-trifluoromethoxyphenylhydrazone; RT/AA: rotenone + antimycin A; OCR: oxygen consumption rate.
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processes were severely compromised. By using the
Seahorse metabolic analyzer, and in keeping with previ-
ous data,28 we observed that leukemic cells have a dis-
tinct preference for oxidative phosphorylation
(OXPHOS), with limited glycolytic capacity. After 6 h of
culture with 10 mM IT-901, a dramatic drop in respiration
was highlighted, leading to a marked decrease in ATP
production (Figure 2D). In line with the hypothesis that
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1882 haematologica | 2017; 102(11)
Figure 3. IT-901 rapidly induces apoptosis selectively in primary chronic lymphocytic leukemia (CLL)  cells. (A) Representative plots and cumulative data of apoptotic
staining with Annexin-V and propidium iodide (PI) of CLL patient cells (n=25) after 24-48 hours (h) of exposure to increasing doses of IT-901 or vehicle (NT). (B)
Apoptotic data were plotted according to the mutational status of IgHV genes [mutated (M) vs. unmutated (UM)] and to the presence of specific genetic abnormalities
(deletion 13/normal vs. deletion 17/mutation in TP53). (C) Total lysates from primary CLL cells cultured alone and exposed to different doses of IT-901 or vehicle
(NT) for 6 h were resolved by SDS-PAGE and expression of pro- and anti-apoptotic proteins and activation of the caspase pathway analyzed using specific antibodies.
Actin was used as a loading control. (D) Cumulative data of apoptosis obtained from Mec-1 (n=12) and OSU-CLL cell lines (n=9) at 24 h and both cell lines (n=21) at
48 h, exposed to increasing doses of IT-901. (E) Total lysates of CLL cell lines, cultured alone and exposed to different doses of IT-901 or vehicle (NT) for 6 h were
resolved by SDS-PAGE and expression of pro- and anti-apoptotic proteins and activation of the caspase pathway analyzed using specific antibodies. Actin was used
as a loading control. (F) Cumulative data of mROS and apoptosis of CLL cell lines (n=6) measured in the presence of N-acetyl-cysteine (NAC) and/or IT-901. (G)
Cumulative data of apoptosis in normal B and T lymphocytes purified from 6 different healthy donors and exposed to increasing doses of IT-901 for the indicated
time points.  FL: full-length; CL: cleaved.
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these metabolic alterations are due to the brusque inter-
ruption of NF-κB transcriptional circuits, as documented
in other models,29 we found significant downmodula-
tion of ATP5A1, the enzyme responsible for ATP synthe-
sis, and of SCO2, a mitochondrial chaperone molecule
that controls assembly of the cytochrome c oxidase sub-
unit II of the electron transfer chain (Figure 2E). A similar
behavior was measured in the cell lines, with a clear
dose-dependent response to IT-901 (Online Supplementary
Figure S2E and F).
IT-901 rapidly induces apoptosis in primary CLL cells,
but not in normal B and T lymphocytes
Induction of mROS with subsequent mitochondrial
damage activated the apoptotic cascade in primary CLL
cells from 25 different patients (Figure 3A). Apoptosis was
time- and dose-dependent, starting at 5 mM after 24-h cul-
ture with IT-901 (Figure 3A). In the CLL cohort examined,
the apoptotic response to IT-901 was apparently inde-
pendent of the mutational status of the IgHV genes and of
the presence of mutations or deletions in TP53, classically
considered as markers of a more aggressive form of the
disease (Figure 3B). Activation of the apoptotic cascade
was confirmed by highlighting caspase 3 cleavage, down-
regulation of anti-apoptotic XIAP and upregulation of pro-
apoptotic BIM proteins, evident at the 5 mM dose and
peaking at 10 mM for primary cells (Figure 3C).
These results were then confirmed in the two CLL cell
line models, which were more sensitive to IT-901, in
keeping with higher constitutive NF-κB activation (Figure
3D and E). Treatment of cell lines with the N-acetyl cys-
teine (NAC), a ROS scavenger, completely abrogated
mROS accumulation and prevented apoptosis, clearly
indicating that mROS are responsible for leukemic cell
death (Figure 3F).
In line with a markedly lower NF-κB expression and
constitutive activation,10 PB, and B and T lymphocytes
purified from healthy donors were less sensitive to apop-
tosis by IT-901 (Figure 3G). After 24h cultures at the 
10 mM concentration, less than 10% (9.8±3.2) of normal B
lymphocytes were dead, as opposed to 44% (44.7±17.7)
of primary CLL cells, indicating the presence of a thera-
peutic window. 
NF-κB silencing recapitulates IT-901 functional effects
To confirm that IT-901 effects on CLL cells were due to
specific NF-κB inhibition, we silenced the p65 subunit of
this complex. This choice was based on evidence of its
high expression and critical role in CLL,3,13,14 also con-
firmed by our results. Lentiviral particles containing a con-
trol GFP-shRNA [Scramble (Scr)], as well as 4 different
GFP-shRNA sequences targeting p65 were used to infect
CLL cell lines. One of the shRNA p65 sequences (shp65A)
significantly inhibited expression of p65 compared to the
Scr sequence, as shown by western blot (Figure 4A). A sec-
ond shRNA p65 sequence (shp65B) was used as an addi-
tional control because of its limited inhibition of expres-
sion of the target protein (Figure 4A). Infected cells ana-
lyzed for viability by flow cytometry at day 6 post infec-
tion, after staining for AnnexinV and PI, showed that
silencing by shp65A significantly enhanced apoptosis of
leukemic cells compared to cells infected with the Scr or
shp65B sequences (Figure 4B). Consistently, expression of
proteins related to the apoptotic pathway, such as XIAP
and Caspase-3, was influenced by p65 silencing, confirm-
ing the results obtained in IT-901 treated primary CLL
cells  (Figure 4A).   
IT-901 inhibits the nurturing properties of nurse-like
cells (NLC)
Given: i) the critical role played by the leukemic
microenvironment in conditioning CLL cell survival and
resistance to therapy; and ii) the central role of NF-κB in
the interactions between CLL cells and stromal/myeloid
components,30 we explored the effects of IT-901 on the
stromal cell line HS-5 and on nurse-like cells (NLC), a pop-
ulation of alternatively activated macrophages typical of
CLL patients.31 
Exposure of both cell types to lipopolysaccharides (LPS)
strongly activated NF-κB, as shown by nuclear transloca-
tion of the p65 subunit, which was almost completely
abrogated by IT-901 treatment (Online Supplementary
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Figure 4. Silencing of the p65 subunit confirms results obtained with IT-901. (A) chronic lymphocytic leukemia (CLL)  cell lines were infected with lentiviral particles
containing plasmids coding for an shRNA scramble (Scr) or shRNA p65 (A and B). Expression of the NF-κB complex was checked by western blot and p50 and p65
expression quantified over actin, showing a significant reduction for p65, while for p50 statistical significance was not reached. Silencing of p65 diminished also the
expression of the anti-apoptotic protein XIAP and of the full-length (FL) Caspase3 protein. Actin was used as a loading control. (B) Apoptosis analysis by flow cytometry
of cell lines infected with shRNA lentiviral particles (n=5). 
A B
Figure S3A), confirming that the drug is effective. We then
co-cultured CLL cells on a layer of autologous NLC, docu-
menting NF-κB activation in both cell types, which was
prevented by IT-901 (Figure 5A). However, exposure of
HS-5 or NLC to IT-901 did not significantly alter their via-
bility (Figure 5B and Online Supplementary Figure S3B).
Consistently, no IT-901-induced modulation of metabolic
genes, mROS and ROS scavengers could be highlighted,
suggesting that CLL cells are uniquely sensitive to the
drug, likely due to their basal metabolic conditions (Online
Supplementary Figure S3C). 
NF-κB signaling in NLC induced transcription of genes
encoding integrins, including ITGA4, ICAM1 and 
VCAM-1, and immune-modulatory molecules, such as
T. Vaisitti et al.
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Figure 5. IT-901 inhibits the nurturing properties of nurse-like cells (NLC). (A) Confocal microscopy
analysis of nuclear factor-kappa B (NF-κB)  activation in NLC alone or co-cultured with autologous
CLL cells in the presence of vehicle (+CLL) or IT-901 (+CLL+IT-901). Cumulative results of the nuclear
p65 fluorescence intensity, in NLC, are reported in the graph. (B) Giemsa staining of vehicle- or 
IT-901-treated NLC. (C and D) mRNA expression level (C; n=8) and phenotypic analysis by flow cytom-
etry (D) of molecules involved in cell-cell interactions (ITGA4, ICAM1 and VCAM1) and immune-mod-
ulatory pathway (CD274 and CD86) in NLC cultured as indicated above. (E) Cumulative data of apop-
tosis of primary leukemic cells co-cultured over HS-5 cells in the presence of increasing doses of IT-
901 for 24h. a.u.: arbitrary units.
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CD274 andCD86.30 Consistent with the inhibitory effects
of IT-901, expression of these target genes (Figure 5C) and
derived proteins (Figure 5D) was inhibited at the 10 mM
dose, indicating that IT-901 prevents the tumor-supportive
phenotype of stromal or NLC cells.
In line with this hypothesis, IT-901 was equally effec-
tive in inducing apoptosis in CLL cells cultured alone or
over a layer of HS-5 or NLC, without measurable differ-
ences in degradation of the NF-κB complex, caspase 3 acti-
vation and modulation of apoptosis-related proteins
(Figure 5E and Online Supplementary Figure S3D and E).
IT-901 co-operates with ibrutinib in inducing apoptosis
of CLL cells
We then asked whether IT-901 potentiated the effects
of the btk inhibitor ibrutinib, selected because of its cur-
rent use in the treatment of CLL patients, including the
high-risk subgroups32 and considering that both drugs tar-
get the same signaling pathway.33 The combination of IT-
901 with ibrutinib markedly enhanced the effects of both
drugs used alone, as determined both by treating CLL cells
alone or after co-culturing leukemic cells on NLC with
consequent protection from spontaneous apoptosis
(Figure 6A and B). As an example, when cultured over
NLC, treatment with ibrutinib 2.5 mM + IT-901 5 mM
induced 48% (48±16.1) of the leukemic cells to undergo
apoptosis after 48 h, compared to 36% (36±14.5) and 33%
(33±17) when treating cells with ibrutinib or IT-901 alone,
respectively (Figure 6B).34
IT-901 limits in vivo growth and spread of CLL cells
We then tested whether treatment with IT-901 of mice
xenografted with CLL cell lines induced an anti-tumor
effect. To address this point, Mec-1 cells were injected in
NSG mice,35 a model considered to be reproducible and
instructive for therapeutic testing.36 Cells were injected in
the tail vein of 8-week old mice, left to engraft for ten
days, before beginning treatment with IT-901 (15 mg/kg,
every day in PBS+GDM) or vehicle only. (A scheme of the
in vivo experiment is reported in Figure 7A). This experi-
ment had two distinct end points: i) at the end of the treat-
ment schedule, vehicle- and IT-901-treated animals were
analyzed for tumor growth and leukemic cell infiltration
of different target organs; ii) the remaining mice were ana-
lyzed for survival.
Examination of the mice immediately after the last
treatment revealed significant differences in tumor growth
and localization. In agreement with previous data,35  vehi-
cle-treated mice showed extensive Mec-1 colonization of
the kidneys, significantly reduced in the IT-901-treated
group (Figure 7B). Moreover, flow cytometry (Figure 7C)
and immunohistochemistry (IHC) analyses, using an anti-
human CD20 antibody (Figure 7D and Online
Supplementary Figure S4A), indicated that IT-901 treatment
significantly reduced the number of Mec-1 cells in liver,
spleen and bone marrow (BM). In line with the specificity
of action of IT-901, a significant decrease in total expres-
sion and nuclear localization of the p65 subunit was
apparent in IT-901-treated mice (Figure 7D and Online
Supplementary Figure S4B). Accordingly, Mec-1 cells
obtained from this group of mice were characterized by
diminished viability compared to cells from vehicle-treat-
ed mice (Figure 7E). 
Kaplan-Meier curves indicated that vehicle-treated mice
were characterized by a significantly shorter survival
(median: 31 days) when compared with those injected
with IT-901 (median: 43 days; P<0.0001) (Figure 7F).
IT-901 is active on primary RS cells and in 
patient-derived xenograft 
We then focused on RS, typically a DLBCL developing
in a minority of patients with a previous or concomitant
diagnosis of CLL.37 
Exposure of RS cells to increasing concentrations of IT-
901 induced apoptosis in a dose-dependent way. These
cells were clearly more sensitive to the NF-κB inhibitor
than CLL cells, independently of the presence of a protec-
tive stromal layer (Figure 8A). The mechanism behind
increased apoptotic responses following IT-901 treatment
Targeting of NF-κB in CLL and RS cells
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Figure 6. IT-901 co-operates with ibrutinib in inducing apoptosis of chronic lymphocytic leukemia (CLL) cells. Cumulative results of apoptosis of primary CLL cells
(n=16) cultured alone (A) or over autologous nurse-like cells (NLC) (B) for 48 hours (h) in the presence of ibrutinib (2.5 mM) and IT-901 (5 and 10 mM) alone or in
combination. Statistical significance of the combined effect of IT-901 and ibrutinib compared to single drugs alone was calculated according to the effect-based strat-
egy, using the Highest Single Agent approach, as described by Foucquier and Guedj.34 *Over single box plot indicates statistical significance compared to untreated
(NT).
A B
was similar to the one highlighted for CLL cells, with
decreased expression of the NF-κB complex, including the
inhibitory subunit. Concomitantly, there was the activa-
tion of the caspase pathway, with modulation of the
expression of pro- and anti-apoptotic proteins (Figure 8B
and Online Supplementary Figure S4C). To prove the effica-
cy of IT-901 in vivo, we then exploited 2 different patient-
derived xenograft (PDX) models, recently established in
the lab. RS cells were s.c. injected in NSG mice and left to
engraft, until tumors became palpable. Mice were then
randomized to receive vehicle or IT-901 treatment, with
the same schedule adopted for the CLL xenografts. Results
indicate that IT-901 significantly reduced tumor growth,
as highlighted by size and weight of tumor masses (Figure
8C). Moreover, a significant reduction in p65 mRNA and
protein levels were evident in IT-901 treated mice (Figure
8D and Online Supplementary Figure S4C). This diminished
expression and activity was also confirmed by checking
T. Vaisitti et al.
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Figure 7. IT-901 limits in vivo
growth and spread of chronic lym-
phocytic leukemia (CLL) cells. (A)
Representative scheme of the in
vivo model. Mec-1 cells were
intravenously injected in tail vein
of NSG mice, left to engraft for ten
days before starting the treatment
with IT-901 or vehicle. (B) Images
of kidneys obtained from vehicle-
or IT-901-treated mice. (C) Mec-1
engraftment in different organs
evaluated by flow cytometry after
labeling of leukemic cells with
anti-human-CD45 and -CD19 anti-
bodies. Cumulative data of
engraftment in kidneys, liver,
spleen and bone marrow (BM)
(n=8 different mice/group). (D)
Immunohistochemical analyses
and quantification of CD20 and
nuclear p65 staining (reported as
percentage of positive cells) in
kidneys of vehicle- or IT-901-treat-
ed mice. (E) Viability of Mec-1
cells, purified from kidneys and
liver of vehicle- or IT-901-treated
mice, analyzed by flow cytometry
(69% vs. 85% of viable cells in kid-
neys and 70% vs. 82% of viable
cells in liver, respectively). (F)
Kaplan-Meier curves showing sur-
vival of mice treated with IT-901
(n=8; red line; 43 days) compared
to vehicle (n=8; blue line; 31
days).  Engr: engraftment; Tx:
treatment; Stop: drug holidays;
Sac: euthanasia.
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localization of the NF-κB complex in cytoplasmic and
nuclear extracts (Figure 8E).
Together, these results provide a proof-of-principle that
IT-901 is efficacious in CLL and RS cells.
Discussion
This work studies the effects of IT-901, a novel inhibitor
of the c-Rel/p65 NF-kB subunits in CLL and in RS. Our
findings suggest that IT-901 induces cell death in both cell
types, with tumor cells being significantly more sensitive
to the drug than normal circulating B cells.
Even if the mechanism of action of this novel inhibitor
is still partially unclear, some conclusions can now be
drawn. Firstly, our data indicate that treatment with IT-
901 reduces NF-κB binding to its consensus DNA
sequences. This effect is particularly evident when consid-
ering p65, which is the most active subunit in CLL cells.
Biochemical analysis of the complex, however, reveals
global degradation of all the subunits, including p50 and
the inhibitory subunit IκB, suggesting that IT-901 binds to
the complex in the cytosol, causing its degradation.
Secondly, IT-901 exposure is followed by an increase of
mROS, which become toxic after a few hours. In princi-
ple, increased mROS could be due to active production or
impaired degradation. On the basis of RT-PCR data indi-
cating that IT-901 decreases expression of genes favoring
ROS scavenging, including catalase, impaired ROS degra-
dation seems to be the main mechanism. According to our
working model, IT-901 would bind the NF-κB complex in
the cytosol, interrupting its cycle, which is constitutively
active in neoplastic B cells, and hence blocking transcrip-
tion of NF-κB-controlled genes. This would limit the cells'
ability to scavenge mROS causing their accumulation over
time, eventually leading over 6 h to mitochondrial dam-
age, highlighted by the finding of altered membrane polar-
ity and of severely impaired mitochondrial respiration
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Figure 8. IT-901 is active on primary Richter
syndrome (RS) cells and in patient-derived
xenograft (PDX). (A) Cumulative data of apop-
tosis of primary or PDX-tumor-derived RS cells.
(B) Western blot analysis of the expression of
the nuclear factor-kappa B (NF-κB) complex,
pro- and anti-apoptotic proteins and caspase-
3 in RS cells exposed to the indicated doses of 
IT-901 for 6 hours (h). Actin was used as load-
ing control. (C) Tumor masses from vehicle- or
IT-901-treated RS-PDX mice compared for
tumor volume (cm3) and weight (g) (6
mice/group; double-flank injected). 
(D) Immunohistochemistry analysis of p65
expression within the tumor mass. Staining
was reported as percentage of positive cells.
(E) Cytoplasmic (C) and nuclear (N) fractions
obtained from RS cells purified from the
tumor mass were resolved by SDS-PAGE and
expression of the NF-κB complex analyzed. β-
tubulin and Lamin A/C were used as cytoplas-
mic and nuclear controls, respectively. 
FL: full-length; CL: cleaved. 
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which  in turn decrease ATP levels. The final result for the
leukemic cell is the cleavage of caspase-3, resulting in
induction of intrinsic apoptosis. The observation that the
ROS scavenger N-acetyl cysteine fully prevents the apop-
totic effects of IT-901 in cell lines confirms the central role
of ROS in the process.
This behavior in the presence of IT-901 seems to be spe-
cific for CLL cells as normal B lymphocytes need signifi-
cantly higher doses to undergo apoptosis, while NLC, as
well as stromal cells do not go into apoptosis with IT-901.
The reason behind this different sensitivity to IT-901
remains unclear, even if it is tempting to speculate a con-
nection to the basal metabolic state of the cell and to basal
levels of mROS. According to this hypothesis, apoptotic
responses to IT-901 would be specific to those cells that
have constitutively high levels of mROS, with rapid toxi-
city following the interruption of genetic circuits regulat-
ing expression of the scavengers. On the contrary, NLC,
which are essentially tumor-associated macrophages, pos-
sess a radically different basal metabolism, with low levels
of mROS. In this context, the genes most affected by NF-
κB inhibition are those coding for surface molecules
important for the crosstalk with tumor cells. 
These findings suggest that IT-901 treatment could be
beneficial by acting through different mechanisms. On the
one hand, IT-901 targets leukemic cells directly, leading to
rapid toxicity and death by apoptosis. On the other hand,
it perturbs molecular circuits driven by the leukemic cells
and aimed at creating favorable growth conditions. The
finding that PD-L1 expression is modulated when
leukemic cells interact with NLC further suggests that IT-
901 helps restore an immunocompetent host.
The third finding favoring further investigation of the
therapeutic properties of IT-901 derives from the observa-
tion of a combined effect when administered together with
the btk inhibitor ibrutinib. While this observation can be
explained on the basis of the convergence of the two drugs
on the same signaling pathway, it is interesting to note that
addition of ibrutinib renders CLL cells sensitive to lower
doses of IT-901, broadening its therapeutic window. 
Using an established xenograft model based on i.v.
injection of Mec-1 cells into NSG mice, we showed that
IT-901 administered as a single agent for two weeks after
documented disease engraftment significantly reduces
tumor burden in all the organs examined. Importantly, a
marked reduction in the nuclear expression of p65 was
observed, confirming NF-κB targeting in vivo.
Lastly, we investigated whether IT-901 is effective also
in experimental models of RS. This is an important issue
as RS remains a disease for which there is an urgent need
for active drugs. One of the difficulties in studying RS is
the lack of experimental models as there are no available
cell lines. For this reason, we exploited two different
patient-derived xenografts established from patients with
RS (T Vaisitti and JN Allan, 2017, manuscript in preparation).
Subsequent adoptive transfer of the lymphoma, which
remained genetically similar to patients' cells, confirmed
successful disease engraftment. By exploiting these mod-
els, we first demonstrated inhibition of NF-κB activation
after IT-901 treatment, with rapid mROS accumulation,
mitochondrial damage and death by apoptosis.
Furthermore, the drug was used in monotherapy to treat
xenografts obtained from RS patients. We found that IT-
901 markedly reduced tumor weight and volume and
inhibited NF-kB expression, suggesting a similar mecha-
nism of action.
In conclusion, this work offers pre-clinical evidence sup-
porting the use of IT-901 in the treatment of CLL and RS
patients.
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